Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

NCT04471844 is registered in ClinicalTrials.gov with NovoCure Ltd. as lead sponsor.

NCT NCT04471844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Lead sponsor
NovoCure Ltd.
Phase
Not applicable
Overall status
Completed
Start date
December 8, 2020
Completion date
February 19, 2026
Enrollment
981 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme